CINECA IRIS Institutional Research Information System

LOPIANO, Leonardo
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 14.924
EU - Europa 11.182
AS - Asia 4.394
SA - Sud America 220
OC - Oceania 183
AF - Africa 68
Continente sconosciuto - Info sul continente non disponibili 10
Totale 30.981
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 14.526
IT - Italia 3.295
CN - Cina 2.524
IE - Irlanda 1.263
SE - Svezia 1.173
DE - Germania 957
FR - Francia 927
GB - Regno Unito 644
FI - Finlandia 518
UA - Ucraina 496
JP - Giappone 434
KR - Corea 416
AT - Austria 362
CA - Canada 354
PL - Polonia 287
ES - Italia 262
VN - Vietnam 261
IN - India 221
NL - Olanda 198
AU - Australia 163
BE - Belgio 140
BR - Brasile 130
RU - Federazione Russa 120
TR - Turchia 102
CH - Svizzera 92
TW - Taiwan 88
GR - Grecia 86
PT - Portogallo 70
SG - Singapore 64
HK - Hong Kong 63
DK - Danimarca 61
RO - Romania 47
IL - Israele 39
AR - Argentina 38
MX - Messico 33
CZ - Repubblica Ceca 29
ID - Indonesia 29
CL - Cile 28
UZ - Uzbekistan 28
NO - Norvegia 27
BG - Bulgaria 23
TH - Thailandia 22
SN - Senegal 21
IR - Iran 20
NZ - Nuova Zelanda 20
RS - Serbia 18
PH - Filippine 15
CO - Colombia 13
MY - Malesia 13
ZA - Sudafrica 13
BY - Bielorussia 12
SI - Slovenia 11
SK - Slovacchia (Repubblica Slovacca) 11
SA - Arabia Saudita 10
HU - Ungheria 9
HR - Croazia 8
TN - Tunisia 8
EG - Egitto 7
CY - Cipro 6
EE - Estonia 6
EU - Europa 6
IS - Islanda 6
AE - Emirati Arabi Uniti 5
BA - Bosnia-Erzegovina 5
MA - Marocco 5
PK - Pakistan 5
AL - Albania 4
KZ - Kazakistan 4
LT - Lituania 4
LU - Lussemburgo 4
MO - Macao, regione amministrativa speciale della Cina 4
MU - Mauritius 4
OM - Oman 4
AP - ???statistics.table.value.countryCode.AP??? 3
BD - Bangladesh 3
BN - Brunei Darussalam 3
BO - Bolivia 3
EC - Ecuador 3
HN - Honduras 3
PA - Panama 3
PE - Perù 3
QA - Qatar 3
SV - El Salvador 3
CM - Camerun 2
GE - Georgia 2
GH - Ghana 2
LB - Libano 2
LV - Lettonia 2
MD - Moldavia 2
MT - Malta 2
NG - Nigeria 2
UY - Uruguay 2
A1 - Anonimo 1
CI - Costa d'Avorio 1
CR - Costa Rica 1
GL - Groenlandia 1
JO - Giordania 1
KE - Kenya 1
KW - Kuwait 1
ME - Montenegro 1
Totale 30.977
Salva come PNG Salva come JPEG
Città #
Chandler 1.972
Beijing 1.551
Dublin 1.237
Houston 1.217
Fairfield 802
Torino 663
Ashburn 614
Ann Arbor 515
Villeurbanne 482
Wilmington 470
Nyköping 424
Princeton 420
Redwood City 420
Woodbridge 397
Medford 396
Jacksonville 392
Vienna 339
Seattle 326
Dearborn 313
Cambridge 293
Warsaw 239
Milan 221
Boston 165
Pisa 164
Dong Ket 162
Rome 139
Boardman 128
Ottawa 123
Turin 114
Shanghai 98
Tokyo 94
New York 83
Nanjing 80
Hangzhou 75
Brussels 73
London 73
Fremont 72
Toronto 72
Madrid 64
Duncan 63
Seoul 63
Taipei 61
Guangzhou 58
Norwalk 58
Chengdu 55
Verona 53
Paris 46
Hefei 42
Wuhan 42
San Diego 38
Falls Church 36
Singapore 36
Washington 34
Chicago 33
Helsinki 33
Hebei 32
Sydney 32
Bologna 31
Lachine 31
Düsseldorf 28
Istanbul 28
Phoenix 28
Berlin 27
Changsha 27
Kunming 27
Zhengzhou 27
Mumbai 26
Athens 25
Dallas 25
Pune 24
Santiago 24
Amsterdam 23
Central District 23
Jinan 23
Mountain View 23
Palermo 23
Silver Spring 23
São Paulo 23
Padova 22
Florence 21
Hamburg 21
Würzburg 21
Barcelona 20
Melbourne 20
Santa Clara 20
Aarhus 19
Buffalo 19
Groslay 19
Redmond 19
Shenyang 19
Bari 18
Nanchang 18
Napoli 18
Nichelino 18
Polska 18
Buenos Aires 17
Chongqing 17
Des Moines 17
Fuzhou 17
Rochester 17
Totale 17.251
Salva come PNG Salva come JPEG
Nome #
Early DEtection of wEaring off in Parkinson disease: The DEEP study 1.436
Parkinson's disease progression at 30 years: a study of subthalamic deep brain-stimulated patients. 684
Impulse control behaviors and subthalamic deep brain stimulation in Parkinson disease 641
Il Bergamini di Neurologia 616
Long-term outcome of subthalamic nucleus DBS in Parkinson's disease: from the advanced phase towards the late stage of the disease? 608
Validation of the Italian version of the Movement Disorder Society - Unified Parkinson's Disease Rating Scale. 589
Subcutaneous immunoglobulin in CIDP and MMN: a short-term nationwide study. 563
Subcutaneous vs intravenous administration of immunoglobulin in chronic inflammatory demyelinating polyneuropathy: an Italian cost-minimization analysis 509
Network Analysis Identifies Disease-Specific Pathways for Parkinson’s Disease 475
Progressive gait ataxia following deep brain stimulation for essential tremor: adverse effect or lack of efficacy? 475
Neuropathy and levodopa in Parkinson's disease: Evidence from a multicenter study 452
Levodopa/carbidopa intestinal gel infusion in advanced Parkinson's disease: a 7-year experience 423
The metabolic signature of C9ORF72-related ALS: FDG PET comparison with nonmutated patients. 373
Levodopa-carbidopa intestinal gel infusion and weight loss in Parkinson's disease 364
Increased risk of impulse control symptoms in Parkinson's disease with REM sleep behaviour disorder 333
Transient effects of 80 Hz stimulation on gait in STN DBS treated PD patients: a 15 months follow-up study. 323
NADPH oxidase 2 (NOX2) enzyme activation in patients with chronic inflammatory demyelinating polyneuropathy 314
Subthalamic deep brain stimulation: clinical and neuropsychological outcomes in mild cognitive impaired parkinsonian patients. 307
Characterization of the thalamic-subthalamic circuit involved in the placebo response through single-neuron recording in Parkinson patients 277
Medical therapy and subthalamic deep brain stimulation in advanced Parkinson's disease: a different long-term outcome? 253
Three novel missense mutations in SLC20A2 associated with idiopathic basal ganglia calcification 251
80 Hz versus 130 Hz subthalamic nucleus deep brain stimulation: effects on involuntary movements. 250
Deep Brain Stimulation of the subthalamic nucleus does not negatively affect social cognitive abilities of patients with Parkinson's disease 244
Subthalamic nucleus deep brain stimulation outcome in young onset Parkinson's disease: a role for age at disease onset? 243
Prospective assessment of peripheral neuropathy in Duodopa-treated parkinsonian patients 243
Self-unawareness of levodopa induced dyskinesias in patients with Parkinson's disease. 243
Transdermal apomorphine permeation from microemulsions: a new treatment in Parkinson's disease 219
Does intraoperative microrecording really increase the risk of hemorrhagic complications in deep brain stimulation? 206
When words are painful: unraveling the mechanisms of the nocebo effect 194
The PRIAMO study: A multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson's disease. 194
Alessitimia e depressione in pazienti con malattia di Parkinson sottoposti a deep brain stimulation del subtalamo: uno studio caso-controllo. 189
Emotion Processing in Parkinson’s Disease: A Three-Level Study on Recognition, Representation, and Regulation 189
Cognitive correlates in amyotrophic lateral sclerosis: a population-based study in Italy. 170
Teaching neurons to respond to placebos 170
Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis 164
Stimulation of the subthalamic area modulating movement and behavior 157
Gut microbiota and metabolome distinctive features in parkinson disease: Focus on levodopa and levodopa carbidopa intrajejunal gel 146
A randomized clinical trial to evaluate the effects of rasagiline on depressive symptoms in non-demented Parkinson's disease patients 145
Nocturnal anomalous movement reduction and sleep microstructure analysis in parkinsonian patients during 1-night transdermal apomorphine treatment. 143
Cleptomania associata a terapia con dopaminoagonista in un paziente affetto da malattia di Parkinson 136
Analisi dei costi della stimolazione cerebrale profonda (DBS) nella malattia di Parkinson: uno studio osservazionale su pazienti italiani. 135
Impulsivities and Parkinson's disease: Delay aversion is not worsened by Deep Brain Stimulation of the Subthalamic Nucleus 135
Alexithymia in patients with Parkinson's disease treated with DBS of the subthalamic nucleus: a case-control study 133
Beyond 35 years of Parkinson’s disease: a comprehensive clinical and instrumental assessment 132
Evidence for a glycidic-lipidic matrix in human neuromelanin, potentially responsible for the enhanced iron sequestering ability of substantia nigra. 131
Caregiver burden and its related factors in advanced Parkinson’s disease: data from the PREDICT study 127
Motor and non-motor outcomes in patients with advanced Parkinson’s disease treated with levodopa/carbidopa intestinal gel: final results of the GREENFIELD observational study 122
Neuropsychological changes 1-year after subthalamic DBS in PD patients: a prospective controlled study 117
Personality and Deep Brain Stimulation of the subthalamic nucleus in Parkinson's disease 113
Nuclear magnetic resonance spectroscopy characterization and iron content determination of human mesencephalic neuromelanin. 112
Open versus hidden medical treatments: the patient's knowledge about a therapy affects the therapy outcome. 111
Analysis of CHCHD2 and CHCHD10 genes in patients with Parkinson’s disease and mitochondrial myopathy. 108
Anhedonia and cognitive impairment in Parkinson's disease: Italian validation of the Snaith-Hamilton Pleasure Scale and its application in the clinical routine practice during the PRIAMO study. 107
Stretch reflex of quadriceps femoris and its relation to rigidity in Parkinson's disease. 106
Electrophysiological properties of thalamic, subthalamic and nigral neurons during the anti-parkinsonian placebo response 105
Reverse blood pressure dipping as marker of dysautonomia in Parkinson disease 102
NADPH Oxidases (NOX) Enzymes Induced Oxidative Stress in CIDP Patients 101
Novel parkin mutations detected in patients with early-onset Parkinson's disease 100
The dominant-subthalamic nucleus phenomenon in bilateral deep brain stimulation for Parkinson's disease: Evidence from a gait analysis study 100
Neurological comorbidity and severity of COVID-19 98
Restricted dissociated sensory loss in a patient with a lateral medullary syndrome: A clinical-MRI study. 95
Alpha-Synuclein protects SH-SY5Y cells from dopamine toxicity 95
Narrative abilities in Parkinson's disease:A pilot study on italian-speaking patients treated with deep brain stimulation of the subthalamic nucleus 94
What Happens When I Watch a Ballet and I Am Dyskinetic? A fMRI Case Report in Parkinson Disease. 94
Safety and efficacy of tolcapone in Parkinson’s disease: systematic review 94
Conscious expectation and unconscious conditioning in analgesic, motor, and hormonal placebo/nocebo responses. 93
Short-term efficacy of ultramicronized palmitoylethanolamide in peripheral neuropathic pain. 91
The placebo effect on bradykinesia in Parkinson's disease with and without prior drug conditioning 91
Deep brain stimulation of subthalamic nucleus: behavioral modifications and familiar relations 90
Validation of the Italian version of carers’ quality-of-life questionnaire for parkinsonism (PQoL Carer) in progressive supranuclear palsy 90
Characterizing advanced Parkinson's disease: OBSERVE-PD observational study results of 2615 patients 89
Antiparkinsonian therapy modifications in PD patients after STN DBS: A retrospective observational analysis 88
NADPH oxidases (NOX) enzymes induced oxidative stress in CIDP patients 87
Pure autonomic failure versus prodromal dysautonomia in Parkinson’s disease: Insights from the bedside 87
Increased prevalence of impulse control disorder symptoms in endocrine diseases treated with dopamine agonists: a cross-sectional study 87
Unilateral and bilateral subthalamic nucleus stimulation in Parkinson's disease: effects on EMG signals of lower limb muscles during walking 86
An original study of mastication in patients with advanced Parkinson disease with and without therapy and deep brain stimulation. 86
Unawareness of dyskinesias in Parkinson’s Disease: Is there a relationship with Theory of Mind dysfunctions? 86
Role of the cingulate cortex in dyskinesias-reduced-self-awareness: An fMRI study on Parkinson's disease patients 86
Proteome analysis of mesencephalic tissues: evidence for Parkinson's disease. 84
Adaptive deep brain stimulation controls levodopa-induced side effects in Parkinsonian patients 84
The PRIAMO study: age- and sex-related relationship between prodromal constipation and disease phenotype in early Parkinson’s disease 84
The control of limb geometry in cat posture. 83
Trait impulsivity and response-inhibition in Parkinson Disease. An fMRI study. 83
Trait impulsivity and response-inhibition in Parkinson Disease. An fMRI piloting study 83
[Role of the cerebellar vermis in the long term habituation of the acoustic startle response in the rat] 82
Inherited thrombophilic conditions, patent foramen ovale and juvenile ischaemic Stroke. 82
Cellular models to investigate biochemical pathways in Parkinson’s disease 82
Cardiovascular autonomic neuropathy and falls in Parkinson disease: a prospective cohort study 82
Discovery and verification of panels of T-lymphocyte proteins as biomarkers of Parkinson's disease 81
Deep brain stimulation in Parkinson's disease: comparison of pre- and post-operative neuropsychological evaluation 80
NADPH oxidases 2 activation in patients with Parkinson's disease 80
Effectiveness of a dance-physiotherapy combined intervention in Parkinson's disease: a randomized controlled pilot trial 80
Deep brain stimulation of the subthalamic nucleus in PD: an analysis of the exclusion causes 79
Apatia in pazienti con malattia di Parkinson sottoposti a DBS del nucleo subtalamico. 79
Autonomic and emotional responses to open and hidden stimulations of the human subthalamic region 78
An original study of mastication in patients with advanced Parkinson disease with and without therapy and deep brain stimulation 78
3 years comparison between duodopa and Deep Brain Stimulation 78
Advanced therapies in Parkinson's disease: Long-term retrospective study 78
Botulinum toxin for Pisa syndrome: An MRI-, ultrasound- and electromyography-guided pilot study 78
Totale 19.613
Salva come PNG Salva come JPEG
Categoria #
all - tutte 78.357
article - articoli 0
book - libri 0
conference - conferenze 10.368
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 88.725
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/20191.222 0 0 0 0 0 0 0 0 0 305 597 320
2019/20204.876 204 188 279 484 455 1.037 528 358 397 362 349 235
2020/20214.153 400 326 324 228 330 337 279 259 470 380 296 524
2021/20224.459 231 180 208 431 234 229 271 225 202 344 961 943
2022/20236.259 688 527 200 609 600 1.520 459 375 598 190 323 170
2023/20242.339 328 527 152 214 260 332 122 211 45 148 0 0
Totale 32.086